BioHarvest Sciences (BHST) to Post Quarterly Earnings on Tuesday

BioHarvest Sciences (NASDAQ:BHST) is projected to post its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to post earnings of ($0.13) per share and revenue of $9.4510 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 8:00 AM ET.

BioHarvest Sciences (NASDAQ:BHST) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. BioHarvest Sciences had a negative net margin of 32.54% and a negative return on equity of 76.03%. The business had revenue of $8.51 million for the quarter, compared to analysts’ expectations of $8.50 million. On average, analysts expect BioHarvest Sciences to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

BioHarvest Sciences Stock Up 2.5%

Shares of BioHarvest Sciences stock traded up $0.06 on Tuesday, reaching $2.21. The stock had a trading volume of 21,778 shares, compared to its average volume of 33,144. The company has a quick ratio of 2.44, a current ratio of 2.96 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $43.46 million, a P/E ratio of -3.75 and a beta of 0.98. The company has a 50 day moving average price of $2.92 and a 200 day moving average price of $3.91. BioHarvest Sciences has a 1 year low of $1.82 and a 1 year high of $12.80.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of BioHarvest Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 18th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $10.00.

Institutional Trading of BioHarvest Sciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new stake in BioHarvest Sciences in the fourth quarter valued at $60,000. Geode Capital Management LLC acquired a new position in shares of BioHarvest Sciences in the 4th quarter valued at about $61,000. HRT Financial LP acquired a new stake in BioHarvest Sciences during the fourth quarter worth about $75,000. Marshall Wace LLP acquired a new stake in BioHarvest Sciences during the fourth quarter worth about $110,000. Finally, Quadrature Capital Ltd purchased a new position in BioHarvest Sciences during the fourth quarter valued at approximately $140,000.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.